Transdermal oxybutynin. A viewpoint by Michael Chancellor.
Chancellor
M
M
University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
D000279:Administration, Cutaneous; D003692:Delayed-Action Preparations; D004890:Erythema / Q000139:chemically induced; D006801:Humans; D008333:Mandelic Acids / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D011537:Pruritus / Q000139:chemically induced; D001745:Urinary Bladder Diseases / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy* / Q000503:physiopathology
D003692:Delayed-Action Preparations; D008333:Mandelic Acids; C032681:desethyloxybutynin; C005419:oxybutynin